Tadekinig alfa is a medication used in this clinical trial to help manage certain rare genetic conditions that cause inflammation in the body. These conditions are known as autoinflammatory diseases, and they can lead to symptoms like fever, rash, and joint pain. Tadekinig alfa works by blocking a specific protein in the body called IL-18, which is involved in causing inflammation. By reducing the activity of this protein, the medication aims to decrease the symptoms and improve the quality of life for patients with these conditions. This trial is focused on understanding how safe and tolerable Tadekinig alfa is for long-term use in patients with specific genetic mutations that lead to these diseases.

NLRC4 Mutation – NLRC4 mutation is a genetic condition that affects the immune system, leading to excessive inflammation. This mutation causes the body’s defense system to become overactive, resulting in recurrent episodes of fever and inflammation in various parts of the body. The inflammation can affect the skin, joints, and internal organs, causing pain and discomfort. Over time, the persistent inflammation can lead to tissue damage. The condition is typically identified in childhood and can vary in severity among individuals. It is a rare condition, often requiring genetic testing for confirmation.

XIAP Deficiency – XIAP deficiency is a genetic disorder that impairs the immune system’s ability to regulate inflammation and cell death. This deficiency can lead to chronic inflammation, recurrent infections, and an increased risk of developing inflammatory bowel disease. The condition is caused by mutations in the XIAP gene, which plays a crucial role in controlling immune responses. Symptoms often begin in childhood and can include fever, diarrhea, and abdominal pain. The severity of the condition can vary, with some individuals experiencing more severe symptoms than others. It is a rare condition that is often diagnosed through genetic testing.